BRENT L SAUNDERS

CIK 1268854 · Chairman of the Board and CEO · last filed 2026-08-07

BRENT L SAUNDERS is a Chairman of the Board and CEO who has filed 79 SEC Form 4 insider transactions across 9 companies since 2007. The most recent filing, for BLCO, was dated Aug 7, 2026. Across all open-market trades the lifetime net is +$1.7M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $40.0M across reported positions. 25 SEC filings were submitted jointly with Actavis plc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$39.99M

Companies

9

Total Filings

79

Lifetime Open-Market Net

$1.66M

Filer Profile

Reported Address
2000 GALLOPING HILL ROAD
C/O SCHERING PLOUGH CORP
KENILWORTH, NJ 07033
Related Filers
Actavis plc — 25 joint filings, latest 2020-05-11
Merck & Co., Inc. — 15 joint filings, latest 2009-11-04
CISCO SYSTEMS, INC. — 8 joint filings, latest 2022-12-12
FOREST LABORATORIES INC — 7 joint filings, latest 2014-07-02
BridgeBio Pharma, Inc. — 5 joint filings, latest 2022-06-24
BLS Investor Group LLC — 1 joint filings, latest 2021-05-18
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BLCO Chairman of the Board and CEO 974,158 $17.25 $16.80M $1.01M 14 2026-08-07
SPRY Director 0 $4.76 $0 -$1.71M 6 2026-06-26
SKIN Director 7,676,591 $0.70 $5.37M $406.1K 10 2025-06-18
CSCO Director 24,143 $112.13 $2.71M $0 7 2022-12-12
BBIO Director 17,600 $72.44 $1.27M $254.9K 4 2022-06-24
Allergan plc (AGN) Delisted Chairman, President and CEO 0 $2.83M 20 2020-05-11
ACT CEO and President 131,862 $49.43 $6.52M $0 2 2015-05-19
Forest Laboratories, LLC (FRX) Delisted CEO & President 0 $12.00 $0 $0 5 2014-07-02
MRK Senior Vice President 50,783 $143.93 $7.31M -$1.12M 8 2009-11-04

Recent Filings

79 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-07 BLCO Mixed +277,648 -$70.9K EDGAR
2026-08-07 BLCO Mixed +277,648 -$70.9K EDGAR
2026-06-26 SPRY Grant (A) $0 EDGAR
2026-05-26 BLCO Tax (F) −2,886 -$45.9K EDGAR
2026-03-10 BLCO Mixed +29,400 $252.0K EDGAR
2026-03-02 BLCO Tax (F) −46,708 -$858.9K EDGAR
2026-02-27 BLCO Grant (A) +327,102 $0 EDGAR
2026-02-25 BLCO Tax (F) −65,444 -$1.18M EDGAR
2025-08-07 BLCO Tax (F) −4,231 -$61.1K EDGAR
2025-07-23 BLCO Grant (A) $0 EDGAR
Showing 110 of 79
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.